Literature DB >> 27611224

The Effect of Commonly Used Excipients on the Epithelial Integrity of Human Cervicovaginal Tissue.

Minlu Hu1,2, Tian Zhou1,2, Charlene S Dezzutti2,3, Lisa C Rohan1,2,3.   

Abstract

Pharmaceutical excipients are widely used in vaginal drug products. The epithelial integrity of the cervicovaginal tissue is important for HIV-1 prevention. However, the effects of excipients on cervicovaginal epithelium remain unknown. This study aims at assessing the effects of vaginal product excipients on the integrity of human cervicovaginal epithelium and on a lead HIV prevention antiretroviral drug, tenofovir (TFV). In the current study, nine excipients commonly used in vaginal formulations were incubated for 6 h with excised human ectocervical tissue. The effects of the excipients were examined by measuring the transepithelial electrical resistance (TEER), epithelial morphology, paracellular/transcellular permeability, and cell viability. The efficacy of TFV for preventing HIV-1 infection in the ex vivo cultured ectocervix was also tested. We found that disodium ethyl-enediaminetetraacetate (EDTA), sorbic acid, and benzoic acid had no effect on the tissue TEER. Butylated hydroxyanisole, glycerin, propylene glycol, methylparaben, and propylparaben slightly to moderately decreased tissue TEER, whereas citric acid significantly decreased the TEER in a time-dependent manner. Tissue morphology observed post-exposure strongly correlated with TEER data; however, a less strong correlation was observed between paracellular permeability and TEER data after exposure to different excipients. In addition, treatment with EDTA, methylparaben, and propylene glycol at tested levels had no effect on the efficacy of TFV in preventing tissue HIV-1 infection. In conclusion, the combined measurements of TEER, morphology, permeability, and viability using human cervicovaginal tissue represent a clinically relevant platform for safety evaluation of excipients and formulated products for HIV-1 prevention.

Entities:  

Keywords:  TEER; cervicovaginal epithelium; excipients; integrity; permeability; tenofovir

Mesh:

Substances:

Year:  2016        PMID: 27611224      PMCID: PMC5067878          DOI: 10.1089/AID.2016.0014

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  62 in total

1.  Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients.

Authors:  A R Neurath; N Strick; Y Y Li; K Lin; S Jiang
Journal:  Biologicals       Date:  1999-03       Impact factor: 1.856

2.  In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.

Authors:  Youssef Gali; Olivier Delezay; Joachim Brouwers; Noura Addad; Patrick Augustijns; Thomas Bourlet; Hind Hamzeh-Cognasse; Kevin K Ariën; Bruno Pozzetto; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  Early events in HIV transmission through a human reconstructed vaginal mucosa.

Authors:  Marielle Bouschbacher; Morgane Bomsel; Estelle Verronèse; Sandrine Gofflo; Yonatan Ganor; Colette Dezutter-Dambuyant; Jenny Valladeau
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

4.  Limitation of the MTT and XTT assays for measuring cell viability due to superoxide formation induced by nano-scale TiO2.

Authors:  Shuguang Wang; Hongtao Yu; Jeffrey K Wickliffe
Journal:  Toxicol In Vitro       Date:  2011-07-21       Impact factor: 3.500

5.  [Improvement of the solubility behavior of problem drugs. 20. The effect of pharmaceutical excipients on the wetability of iomeglamic acid].

Authors:  F Fahr; G Zessin; H Kala; G Fries
Journal:  Pharmazie       Date:  1989-08       Impact factor: 1.267

6.  Effects of excipients on the crystallization of pharmaceutical compounds during lyophilization.

Authors:  D J Korey; J B Schwartz
Journal:  J Parenter Sci Technol       Date:  1989 Mar-Apr

7.  Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations.

Authors:  Beata Stanisz; Katarzyna Regulska; Jagoda Kania; Piotr Garbacki
Journal:  Drug Dev Ind Pharm       Date:  2012-02-20       Impact factor: 3.225

8.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

9.  Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse.

Authors:  Thomas R Moench; Russell J Mumper; Timothy E Hoen; Mianmian Sun; Richard A Cone
Journal:  BMC Infect Dis       Date:  2010-11-18       Impact factor: 3.090

Review 10.  Virus entry: open sesame.

Authors:  Mark Marsh; Ari Helenius
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

View more
  5 in total

Review 1.  On-demand microbicide products: design matters.

Authors:  Sravan Kumar Patel; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

Review 2.  Relating Advanced Electrospun Fiber Architectures to the Temporal Release of Active Agents to Meet the Needs of Next-Generation Intravaginal Delivery Applications.

Authors:  Kevin M Tyo; Farnaz Minooei; Keegan C Curry; Sarah M NeCamp; Danielle L Graves; Joel R Fried; Jill M Steinbach-Rankins
Journal:  Pharmaceutics       Date:  2019-04-03       Impact factor: 6.321

Review 3.  The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models.

Authors:  Carolina Herrera
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

4.  Impact of vaginal douching products on vaginal Lactobacillus, Escherichia coli and epithelial immune responses.

Authors:  Helai Hesham; Alissa J Mitchell; Agnes Bergerat; Kristin Hung; Caroline M Mitchell
Journal:  Sci Rep       Date:  2021-11-29       Impact factor: 4.379

5.  Effect of commercial vaginal products on the growth of uropathogenic and commensal vaginal bacteria.

Authors:  Kristin J Hung; Patricia L Hudson; Agnes Bergerat; Helai Hesham; Namit Choksi; Caroline Mitchell
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.